Jim Cramer
Medicare wants to cut the price on an Eli Lilly drug. What it means for LLY shares
Eli Lilly headquarters in Indianapolis, Indiana, US, on Wednesday, May 3, 2023. Eli Lilly & Co.’s shares climbed in early US trading after its experimental drug for Alzheimer’s slowed the progress of the disease in a final-stage trial, paving the way for the company to apply for US approval. AJ Mast | Bloomberg | Getty […]
Read More
Here are the 8 trades and 3 price-target changes we made during a busy week
Our portfolio experienced a flurry of adjustments in a week dominated by Nvidia’s (NVDA) quarterly results Wednesday evening and Federal Reserve Chairman Jerome Powell’s Jackson Hole address Friday. Here’s a day-by-day look at the trades and price-target changes, and what motivated each decision. Monday Monday proved to be a harbinger for the rest of the […]
Read More
3 things point to better times ahead for this maker of X-Ray and MRI machines
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Friday’s key moments. 1. Wall Street saw some volatility Friday around Federal Reserve Chairman Jerome Powell’s morning speech from the central bank conference in Jackson Hole, Wyoming. Powell said inflation is still “too […]
Read More
This biotech name is one of Jim Cramer’s favorite stocks and he thinks it can go even higher
Regeneron Pharmaceuticals (REGN) rose Monday after the Food and Drug Administration approved a higher-dose formulation of Eylea, the company’s macular degeneration treatment. If you like this story, sign up for Jim Cramer’s Top 10 Morning Thoughts on the Market email newsletter for free. CNBC’s Jim Cramer said on “Squawk on the Street” that Regeneron is […]
Read More
We’re buying more of 2 stocks, deploying some of our cash pile in an oversold market
We’re putting a little more of our big cash position to work Monday into the oversold market. Source
Read More
Even with China’s financial troubles, Cramer states its market place would not collapse
CNBC’s Jim Cramer on Thursday explained to investors he does not feel China’s current market will collapse irrespective of the country’s new weaker-than-anticipated economic figures and issues with its actual estate sector, exclusively Region Yard, one particular of the most significant nonstate-owned builders that not too long ago skipped two payments on dollar bonds. “Now […]
Read More
Here’s a rapid-fire update on all 36 stocks in the Club’s portfolio, including 2 recent buys
During the Investing Club’s August Monthly Meeting, Jim Cramer provided his latest thinking on all 36 names in his Charitable Trust. Source
Read More
These are the top 5 performing Club stocks from mid-July to our August Monthly Meeting
Since the CNBC Investing Club’s July Monthly Meeting, the stock market has seesawed up and then down on a slew of quarterly earnings results and inflation data. That’s left Wall Street struggling this month. Here’s a look at the best performers from the Club’s 36 holdings from the market close after the July 12 meeting […]
Read More
Activists ease up on Salesforce — plus, 10 other Club stocks traded by Wall Street pros
The extraordinary activist-investor interest in Salesforce (CRM) eased further in the second quarter, according to the latest regulatory filings from influential Wall Street pros. These big-name investors also made moves in nine other Club stocks during a strong three-month stretch that ended the best first half for the market in years. Starting with Salesforce, Dan […]
Read More
Eli Lilly gets a new price target after a big rally. Should I buy more shares?
Here’s our Club Mailbag email [email protected] — so you send your questions directly to Jim Cramer and his team of analysts. We can’t offer personal investing advice. We will only consider more general questions about the investment process or stocks in the portfolio or related industries. This week’s question: I’m learning so much from the […]
Read More